The Chemours Company (CC) Proxy Filing summary

Executive summary

• Refreshed business strategy, Pathway to Thrive, launched in 2024, focusing on Operational Excellence, Enabling Growth, Portfolio Management, and Strengthening the Long Term.

• New CEO Denise Dignam and CFO Shane Hostetter appointed in 2024, with additional leadership changes to support strategy execution.

• Achieved solid financial results in 2024, including double-digit growth in Opteon™ refrigerants and cost savings in Titanium Technologies.

• Significant progress made in remediating internal control weaknesses, with effective controls as of year-end 2024.

Voting matters and shareholder proposals

• Shareholders to vote on election of 12 directors, advisory approval of executive compensation, ratification of PwC as auditor, elimination of supermajority voting provisions, and a shareholder proposal on biodiversity impact assessments.

• Board recommends voting for all management proposals and against the biodiversity proposal, citing existing robust environmental assessment processes.

Board of directors and corporate governance

• Board comprises 12 nominees, 11 of whom are independent, with diverse skills in finance, technology, sustainability, and governance.

• Ongoing board refreshment with new directors added annually since 2021; focus on diversity and expertise.

• Board committees (Audit, CLDC, NCG, EHS&O) are fully independent and oversee key areas including risk, compensation, governance, and safety.

• Enhanced Code of Conduct and Speak-Up Policy implemented in 2024.